Physicians prefer combo Rxs to treat heart disease
More than half of physicians prefer two drugs in a single-pill combination for the treatment of cardiovascular disease, and managed care organizations (MCOs) said they would relegate Novartis' Exforge, which combines amlodipine (Norvasc, Pfizer) and valsartan (Diovan, Novartis), to Tier 3 of their formularies, according to a new report issued by Decision Resources.
More than half of physicians prefer two drugs in a single-pill combination for the treatment of cardiovascular disease, and managed care organizations (MCOs) said they would relegate Novartis' Exforge, which combines amlodipine (Norvasc, Pfizer) and valsartan (Diovan, Novartis), to Tier 3 of their formularies, according to a new report issued by Decision Resources. The reportCombination Cardiovascular Drugs: A Survey of PCPs, Cardiologists, and MCO Pharmacy Directorsfound that 56% of primary care physicians and 53% of cardiologists surveyed said they would like more than two drugs in a single-pill combination. When triple-drug single-pill combinations were considered, physicians prefer the combination of ACE inhibitor, beta-blocker, and statin. The report found that 65% of MCOs said they would place Exforge on Tier 3, while 20% say they would exclude the agent from their formularies.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
